Saturday 17 October 2026
Export LIMN’s income statement to Excel — free account
Liminatus Pharma Inc.
LIMN Healthcare Biotechnology
In the quarter to June 2026, EPS fell 717.0%, free cash flow grew 89.0% and total debt was flat, each against the same quarter a year earlier.
3.04
0.17
−5.30%
Follow LIMN
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
0.21 | 0.05 |
Net Debt/EBITDA |
(5.98) | (0.37) |
Debt/Assets |
369.26% | 281.30% |
Debt/Equity |
(1.03) | (0.15) |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.41 | 0.98 |
Capex/Depreciation |
— | (7.28) |
Interest Coverage |
(9.83) | (13.75) |
| 0.00% | 70.02% | |
| 0.00% | (344.72%) | |
ROIC |
(360.95%) | 0.00% |
Return on Tangible Assets |
18.22% | 104.30% |
Average Days of Receivables |
0.00 | — |
Research and Development Expense of Revenue |
0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Free Cash Flow per Share |
(4.15) | (21.00) |
Cash per Share |
0.16 | 0.71 |
Shareholders Equity per Share |
(55.26) | (20.66) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(55.26) | (20.66) |
Free Cash Flow |
(1.45) | (9.98) |
Working Capital |
(19.47) | (9.80) |
Capital Expenditures |
— | (0.01) |
Net Current Asset Value |
(19.47) | (9.83) |
| Other line items | ||
Quick Ratio |
0.15 | 0.03 |
Depreciation/Fixed assets |
0.00 | 0.15 |
Cash ROIC |
(210.55%) | 124.17% |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(4.15) | (20.97) |
Capex per Share |
0.00 | (0.03) |
Average Payables |
— | 1.03 |
Average Assets |
— | 2.96 |
Average Common Equity |
— | (14.58) |
Capex to Sales |
— | 0.00 |
Columns are period end dates